Qube Research & Technologies Ltd Sells 17,083 Shares of BioAtla, Inc. (NASDAQ:BCAB)
Qube Research & Technologies Ltd decreased its position in shares of BioAtla, Inc. (NASDAQ:BCAB – Get Rating) by 48.8% in the 1st quarter, Holdings Channel reports. The fund owned 17,936 shares of the company’s stock after selling 17,083 shares during the quarter. Qube Research & Technologies Ltd’s holdings in BioAtla were worth $90,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Los Angeles Capital Management LLC bought a new position in shares of BioAtla during the 1st quarter worth $333,000. Woodline Partners LP grew its stake in shares of BioAtla by 196.1% during the 4th quarter. Woodline Partners LP now owns 446,141 shares of the company’s stock worth $8,758,000 after acquiring an additional 295.446 shares during the period. Russell Investments Group Ltd. bought a new position in shares of BioAtla during the 1st quarter worth $286,000. SG Americas Securities LLC grew its stake in shares of BioAtla by 165.0% during the 1st quarter. SG Americas Securities LLC now owns 13,524 shares of the company’s stock worth $68,000 after acquiring an additional 8,421 shares during the period. Finally, Nisa Investment Advisors LLC purchased a new stake in BioAtla during the 1st quarter worth about $167,000. Institutional investors own 70.79% of the company’s stock.
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on BCAB. HC Wainwright dropped their price objective on BioAtla from $25.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, August 10th. Credit Suisse Group cut BioAtla from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $35.00 to $5.00 in a report on Thursday, May 5th.
Insider Buying and Selling
In related news, CEO Jay M. Phd Short purchased 26,350 shares of BioAtla stock in a transaction that occurred on Friday, August 12th. The shares were acquired at an average cost of $7.84 per share, for a total transaction of $206,584.00. Following the transaction, the chief executive officer now directly owns 1,396,556 shares in the company, valued at $10,948,999.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Jay M. Phd Short purchased 26,350 shares of BioAtla stock in a transaction that occurred on Friday, August 12th. The shares were acquired at an average cost of $7.84 per share, for a total transaction of $206,584.00. Following the transaction, the chief executive officer now directly owns 1,396,556 shares in the company, valued at $10,948,999.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Christian Vasquez acquired 14,152 shares of the business’s stock in a transaction dated Tuesday, June 7th. The stock was acquired at an average price of $3.04 per share, for a total transaction of $43,022.08. Following the completion of the transaction, the insider now owns 38,677 shares in the company, valued at approximately $117,578.08. The disclosure for this purchase can be found here. Insiders have purchased a total of 79.584 shares of company stock worth $360.445 in the last ninety days. 14.80% of the stock is owned by insiders.
BioAtla Stock Down 1.8%
NASDAQ:BCAB opened at $9.08 on Monday. The business’s 50-day moving average price is $4.99 and its two-hundred day moving average price is $4.50. BioAtla, Inc. has a twelve month low of $2.01 and a twelve month high of $42.28. The stock has a market cap of $339.72 million, a P/E ratio of -3.33 and a beta of 1.60.
BioAtla (NASDAQ:BCAB – Get Rating) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.07). During the same quarter in the previous year, the firm earned ($0.90) earnings per share. On average, equity research analysts expect that BioAtla, Inc. will post -2.87 EPS for the current fiscal year.
BioAtla Profile
(Get Rating)
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer.
Featured Stories
Want to see what other hedge funds are holding BCAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioAtla, Inc. (NASDAQ:BCAB – Get Rating).
Receive News & Ratings for BioAtla Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BioAtla and related companies with MarketBeat.com’s FREE daily email newsletter.